- Home
- MIRM vs CNOBP Comparison
MIRM vs CNOBP Comparison
Compare MIRM & CNOBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- CNOBP
- Stock Information
- Founded
- MIRM 2018
- CNOBP N/A
- Country
- MIRM United States
- CNOBP United States
- Employees
- MIRM N/A
- CNOBP 493
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- CNOBP Major Banks
- Sector
- MIRM Health Care
- CNOBP Finance
- Exchange
- MIRM Nasdaq
- CNOBP Nasdaq
- Market Cap
- MIRM 1.9B
- CNOBP N/A
- IPO Year
- MIRM 2019
- CNOBP N/A
- Fundamental
- Price
- MIRM $40.00
- CNOBP $22.00
- Analyst Decision
- MIRM Strong Buy
- CNOBP
- Analyst Count
- MIRM 11
- CNOBP 0
- Target Price
- MIRM $58.55
- CNOBP N/A
- AVG Volume (30 Days)
- MIRM 447.2K
- CNOBP N/A
- Earning Date
- MIRM 05-07-2025
- CNOBP N/A
- Dividend Yield
- MIRM N/A
- CNOBP N/A
- EPS Growth
- MIRM N/A
- CNOBP N/A
- EPS
- MIRM N/A
- CNOBP N/A
- Revenue
- MIRM $336,888,000.00
- CNOBP N/A
- Revenue This Year
- MIRM $29.51
- CNOBP N/A
- Revenue Next Year
- MIRM $20.27
- CNOBP N/A
- P/E Ratio
- MIRM N/A
- CNOBP N/A
- Revenue Growth
- MIRM 80.76
- CNOBP N/A
- 52 Week Low
- MIRM $23.14
- CNOBP N/A
- 52 Week High
- MIRM $54.23
- CNOBP N/A
- Technical
- Relative Strength Index (RSI)
- MIRM 41.05
- CNOBP 47.49
- Support Level
- MIRM $38.22
- CNOBP $21.81
- Resistance Level
- MIRM $40.14
- CNOBP $22.82
- Average True Range (ATR)
- MIRM 2.24
- CNOBP 0.34
- MACD
- MIRM 0.07
- CNOBP 0.07
- Stochastic Oscillator
- MIRM 48.50
- CNOBP 94.47
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About CNOBP ConnectOne Bancorp Inc. Depositary Shares each representing a 1/40th interest in a share of 5.25% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock Series A
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.